RESUMEN
The expression of Bruton tyrosine kinase (BTK) in B cells and innate immune cells provides essential downstream signaling for BCR, Fc receptors, and other innate immune cell pathways. The topical covalent BTK inhibitor PRN473 has shown durable, reversible BTK occupancy with rapid on-rate and slow off-rate binding kinetics and long residence time, resulting in prolonged, localized efficacy with low systemic exposure in vivo. Mechanisms of PRN473 include inhibition of IgE (FcεR)-mediated activation of mast cells and basophils, IgG (FcγR)-mediated activation of monocytes, and neutrophil migration. In vivo, oral PRN473 was efficacious and well tolerated in the treatment of canine pemphigus foliaceus. In this study, we evaluated in vitro selectivity and functionality, in vivo skin Ab inflammatory responses, and systemic pharmacology with topically administered PRN473. Significant dose-dependent inhibition of IgG-mediated passive Arthus reaction in rats was observed with topical PRN473 and was maintained when given 16 h prior to challenge, reinforcing extended activity with once-daily administration. Similarly, topical PRN473 resulted in significant dose-dependent inhibition of the mouse passive cutaneous anaphylaxis IgE-mediated reaction. Multiday treatment with topical PRN473 in rodents resulted in low-to-no systemic accumulation, suggesting that efficacy was mainly due to localized exposure. Reduced skin Ab inflammatory activity was also confirmed with oral PRN473. These preclinical studies provide a strong biologic basis for targeting innate immune cell responses locally in the skin, with rapid onset of action following once-daily topical PRN473 administration and minimal systemic exposure. Dose-dependent inhibition in these preclinical models of immune-mediated skin diseases support future clinical studies.
Asunto(s)
Agammaglobulinemia Tirosina Quinasa , Reacción de Arthus , Anafilaxis Cutánea Pasiva , Inhibidores de Proteínas Quinasas , Enfermedades de la Piel , Animales , Femenino , Humanos , Ratones , Ratas , Administración Cutánea , Administración Oral , Agammaglobulinemia Tirosina Quinasa/antagonistas & inhibidores , Reacción de Arthus/tratamiento farmacológico , Reacción de Arthus/inmunología , Reacción de Arthus/patología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Anafilaxis Cutánea Pasiva/efectos de los fármacos , Inhibidores de Proteínas Quinasas/administración & dosificación , Piel/efectos de los fármacos , Piel/inmunología , Piel/patología , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/patologíaRESUMEN
The use of herbal supplements that promise to improve immune health has gained popularity among dermatology patients. However, there is little to no evidence that herbal supplements improve dermatologic conditions. Several in vitro and in vivo studies have shown that Spirulina platensis, Aphanizomenon flos-aqua, Chlorella, Echinacea, and alfalfa activate immune cells via certain cytokines and chemokines. Case reports suggest the association of ingesting immunostimulatory herbs and the clinical onset or flares of diseases characterized by an exaggerated immune response such as lupus erythematosus, dermatomyositis, and autoimmune blistering disorders. Therefore, it is imperative to investigate the prevalence of herbal supplement use in this patient population. In addition, in vitro studies should examine the underlying mechanisms by which herbs stimulate immune pathways that are already overactive in autoimmune patients.
Asunto(s)
Adyuvantes Inmunológicos/efectos adversos , Enfermedades Autoinmunes/inducido químicamente , Suplementos Dietéticos/efectos adversos , Enfermedades de la Piel/inducido químicamente , Adyuvantes Inmunológicos/farmacología , Animales , Aphanizomenon , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/fisiopatología , Chlorella , Citocinas/metabolismo , Progresión de la Enfermedad , Echinacea/efectos adversos , Humanos , Medicago sativa/efectos adversos , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/fisiopatología , SpirulinaRESUMEN
Eosinophilic dermatoses encompass a broad spectrum of diseases of different etiologies hallmarked by eosinophilic infiltration of the skin and/or mucous membranes, with or without associated blood eosinophilia. The wide range of dermatological manifestations of this spectrum, including nodules and plaques, pustules, blisters, ulcers, and urticarial lesions, is reflected in a non-univocal classification system. We identified six groups of eosinophilic dermatoses based on the predominant anatomic level of involvement: (1) epidermal; (2) of the dermal-epidermal junction; (3) dermal; (4) of the hypodermis and muscle fascia; (5) of the pilosebaceous unit; and (6) vascular/perivascular. We review clinicopathologic features and management of diseases belonging to each group, particularly: (1) pemphigus herpetiformis and atopic dermatitis as prototypes of the epidermal group; (2) bullous pemphigoid as prototypic eosinophilic dermatosis of the dermal-epidermal junction; (3) eosinophilic cellulitis (Wells syndrome), hypereosinophilic syndromes, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, eosinophilic dermatosis of hematologic malignancy and chronic spontaneous urticaria as paradigmatic dermal eosinophilic dermatoses; (4) eosinophilic fasciitis as an eosinophilic dermatosis with predominant involvement of the hypodermis and muscle fascia; (5) eosinophilic pustular folliculitis as a model of the pilosebaceous unit involvement; and (6) granuloma faciale, angiolymphoid hyperplasia with eosinophilia, and eosinophilic granulomatosis with polyangiitis, belonging to the vascular/perivascular group.
Asunto(s)
Eosinofilia/diagnóstico , Eosinofilia/terapia , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/terapia , Productos Biológicos/uso terapéutico , Biomarcadores/análisis , Fármacos Dermatológicos/uso terapéutico , Eosinofilia/inmunología , Eosinofilia/patología , Eosinófilos/inmunología , Humanos , Inmunohistoquímica/métodos , Inmunosupresores/uso terapéutico , Fototerapia/métodos , Piel/inmunología , Piel/patología , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/patología , Resultado del TratamientoRESUMEN
PURPOSE: Although scientific articles mention the impact of psychological stress on skin diseases, few review the latest research on factors involved in this correlation. The skin actively responds to psychological stress, with involvement of skin immune cells, hormones, neurotransmitters. Skin immune cells actively regulate tissue inflammation with their proinflammatory and anti-inflammatory effects. Stress-induced skin reactions primarily include cytokine secretion (e.g. interleukin-6, interleukin-1, interferon-γ) and activation of skins peripheral corticotropin-releasing hormone (CRH)-proopiomelanocortin (POMC)-adrenocorticotropic hormone (ACTH)-corticosteroids axis, which leads to acute/chronic secretion of corticosteroids in the skin. METHODS: This narrative review presents the current knowledge and latest findings regarding the impact of psychological stress on skin diseases, including information concerning psychoneuroimmune factors in stress-induced skin responses. Recent articles published in English available through the PubMed database and other prominent literature are discussed. FINDINGS: Stress mediators, including cortisol, ACTH, and CRH from hypothalamus-pituitary-adrenal axis activation, induce various skin immune responses. Skin cells themselves can secrete these hormones and participate in skin inflammation. Thus, the local skin CRH-POMC-ACTH-corticosteroids axis plays a prominent role in stress-induced responses. Also, keratinocytes and fibroblasts produce hypothalamic and pituitary signal peptides and express receptors for them (CRH with receptors and POMC degradation peptides with melanocortin receptors), which allows them to respond to CRH by activating the POMC gene, which is then followed by ACTH and subsequently corticosteroids excretion. In addition, keratinocytes can express receptors for neurotransmitters (e.g. adrenaline, noradrenaline, dopamine, histamine, acetylcholine), neurotrophins, and neuropeptides (e.g. substance P, nerve growth factor), which are important in linking psychoneuroimmunologic mechanisms. IMPLICATIONS: Psychoneuroimmunology provides an understanding that the skin is target and source of stress mediators. This locally expressed complex stress-induced network has been confirmed as active in many skin diseases (e.g. vulgar psoriasis, atopic dermatitis, chronic urticaria, human papillomavirus infections/warts, hair loss, acne). Skin reactions to stress and its influence on skin diseases may have implications for disease severity and exacerbation frequency, given the effect of locally secreted corticosteroids and other mediators that affect skin integrity, inflammation, and healing potential. Studies have also shown that introducing psychiatric treatment (drugs or psychotherapeutic methods) can have positive effects on dermatologic diseases influenced by psychological stress exposure. We hope this review provides clinicians and scientists with more complete background for further research in this field of skin psychoneuroimmunology.
Asunto(s)
Hormonas/metabolismo , Neurotransmisores/metabolismo , Piel/inmunología , Piel/metabolismo , Estrés Psicológico/inmunología , Estrés Psicológico/metabolismo , Animales , Humanos , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/metabolismoRESUMEN
There is a long history of utilization of phototherapy for treatment of skin conditions. Because of its longer wavelength, UVA1 phototherapy is able to penetrate into the dermis and subcutis. This depth of penetration, combined with its unique immunomodulating properties, makes UVA1 an effective treatment modality for many immune-mediated skin diseases. In some cases, it performs better than other types of phototherapy.
Asunto(s)
Inmunomodulación/inmunología , Terapia PUVA/estadística & datos numéricos , Enfermedades de la Piel/tratamiento farmacológico , Humanos , Enfermedades de la Piel/inmunologíaRESUMEN
Skin is larger than any other organ in humans. Like other organs, various bacterial, viral, and inflammatory diseases, as well as cancer, affect the skin. Skin diseases like acne, atopic dermatitis, and psoriasis often reduce the quality of life seriously. Therefore, effective treatment of skin disorders is important despite them not being life-threatening. Conventional medicines for skin diseases include corticosteroids and antimicrobial drugs, which are effective in treating many inflammatory and infectious skin diseases; however, there are growing concerns about the side effects of these therapies, especially during long-term use in relapsing or intractable diseases. Hence, many researchers are trying to develop alternative treatments, especially from natural sources, to resolve these limitations. Bee venom (BV) is an attractive candidate because many experimental and clinical reports show that BV exhibits anti-inflammatory, anti-apoptotic, anti-fibrotic, antibacterial, antiviral, antifungal, and anticancer effects. Here, we review the therapeutic applications of BV in skin diseases, including acne, alopecia, atopic dermatitis, melanoma, morphea, photoaging, psoriasis, wounds, wrinkles, and vitiligo. Moreover, we explore the therapeutic mechanisms of BV in the treatment of skin diseases and cytotoxic effects of BV on skin disease-causing pathogens, including bacteria, fungi and viruses.
Asunto(s)
Venenos de Abeja/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Animales , Venenos de Abeja/farmacología , Fármacos Dermatológicos/farmacología , Humanos , Enfermedades de la Piel/inmunologíaAsunto(s)
Fototerapia/métodos , Enfermedades de la Piel/terapia , Linfocitos T/efectos de la radiación , Rayos Ultravioleta , Apoptosis/inmunología , Apoptosis/efectos de la radiación , Daño del ADN/inmunología , Daño del ADN/efectos de la radiación , Humanos , Células Jurkat , Fototerapia/instrumentación , Enfermedades de la Piel/inmunología , Linfocitos T/inmunologíaRESUMEN
Mast cells (MCs) are the principal effector cells of IgE-mediated allergy. IL-33 is released by resident skin cells as alarmin upon tissue damage or allergen contact. Owing to their pronounced receptor expression, MCs are important targets of IL-33 action, but consequences for skin MCs are ill-defined, especially upon chronic exposure to IL-33. Mimicking the inflammatory milieu of skin disorders, we found that persistent exposure to IL-33 (over a 5-week period) strengthened skin MC numbers through accelerated cell-cycle progression and restriction of apoptosis. Conversely, IL-33 attenuated degranulation and FcεRI expression, potentially as a feedback to chronic "alarmin" exposure. Interestingly, the negative impact on histamine release was counterbalanced by amplified histamine production. Considering the clinical significance of histamine and scarce information on its regulation, we explored the molecular underpinnings. IL-33 induced swift phosphorylation of p38 and JNK (but not of ERK1/2 or AKT), and stimulated histidine decarboxylase expression. Combining pharmacological inhibition and kinase elimination by Accell-facilitated RNA interference in skin MCs revealed a p38-dependent, but JNK-independent mechanism. Collectively, IL-33 exerts multifaceted effects on cutaneous MCs at a post-maturation stage. The IL-33-skin MC axis may contribute to and balance inflammation in chronic skin disorders.
Asunto(s)
Histamina/biosíntesis , Hipersensibilidad/inmunología , Inflamación/inmunología , Interleucina-33/metabolismo , Mastocitos/metabolismo , Enfermedades de la Piel/inmunología , Piel/patología , Ciclo Celular , Degranulación de la Célula , Células Cultivadas , Histidina Descarboxilasa/metabolismo , Humanos , Inmunoglobulina E/metabolismo , Mastocitos/patología , Interferencia de ARN , Receptores de IgE/metabolismo , Yin-Yang , Proteínas Quinasas p38 Activadas por Mitógenos/genética , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismoRESUMEN
Malnutrition-associated dermatoses including necrolytic migratory erythema (NME) and pellagra share common clinicopathological features; in particular, necrolytic changes in the upper epidermis. Here, we report the involvement of autophagy in the development of necrolysis in three patients with malnutrition-associated dermatoses. First, we examined an autophagy-specific molecule, microtubule-associated protein light chain 3 (LC3), using a monoclonal antibody. LC3 was strongly expressed in the granular layers of the active border, and less intensely observed in the perilesional areas. Little LC3 staining or only background levels were observed in control skin diseases including atopic dermatitis (n = 4), psoriasis vulgaris (n = 3), basal cell carcinoma with amyloid deposits (n = 3) and squamous cell carcinoma (n = 3). Electron microscopic observations revealed the presence of autophagosome-like structures in the necrolytic areas. No apoptotic signals were observed in the necrolytic lesion using the terminal deoxynucleotidyl transferase dUTP nick end labeling method. Epidermal Langerhans cells determined by anti-CD1a antibody were markedly decreased in number. Our observations suggest the possibility that malnutrition-associated necrolysis, as exemplified by NME and pellagra, may be induced by autophagy.
Asunto(s)
Autofagia/inmunología , Desnutrición/inmunología , Terapia Nutricional , Enfermedades de la Piel/inmunología , Adulto , Anciano , Biopsia , Femenino , Humanos , Queratinocitos/inmunología , Masculino , Desnutrición/terapia , Persona de Mediana Edad , Piel/citología , Piel/inmunología , Piel/patología , Enfermedades de la Piel/patología , Enfermedades de la Piel/terapiaRESUMEN
Many skin disorders have been associated with nutritional deficiencies, as well as many skin disorders, have been associated to diet-related immune mechanisms. The food can be a source of beneficial substances for health that act in very precise ways on the body and the functioning of each individual cells, tissues, and organs.
Asunto(s)
Prestación Integrada de Atención de Salud/métodos , Dermatología/métodos , Dieta Saludable , Terapia Nutricional/métodos , Enfermedades de la Piel/dietoterapia , Humanos , Estado Nutricional , Valor Nutritivo , Ingesta Diaria Recomendada , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/fisiopatologíaRESUMEN
Refractory cutaneous warts are difficult to eliminate. In situ photo-immunotherapy (ISPI) is an innovative treatment concept combining local photothermal therapy (PTT) and topical immunotherapy using imiquimod. To compare the efficacy of ISPI vs topical imiquimod alone, a prospective randomized controlled trial was performed with patients suffering from refractory cutaneous warts. In both groups, approximately 50% of the skin surface containing warts was treated for 6 weeks. On the basis of topical imiquimod, ISPI includes an additional 808 nm laser irradiation. Treatment response, temperatures during irradiation and histopathologic examination were evaluated. The complete response rate in the ISPI-group (22/36, 61.1%) was significantly higher than in the imiquimod alone group (11/34, 32.4%). In the ISPI-group, the mean maximum temperature was 44.5 ± 5.1°C, and obvious lymphocytic infiltration was found in the perivasculature of the dermis. There was no recurrence or worsening in both groups during the 12-month follow-up. No obvious adverse reaction was observed. This study demonstrates that ISPI can be used as an effective and safe treatment modality for refractory cutaneous warts.
Asunto(s)
Imiquimod/farmacología , Inmunoterapia , Fototerapia , Enfermedades de la Piel/inmunología , Verrugas/inmunología , Adolescente , Adulto , Anciano , Niño , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Imiquimod/uso terapéutico , Masculino , Persona de Mediana Edad , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/patología , Temperatura , Resultado del Tratamiento , Verrugas/tratamiento farmacológico , Verrugas/patología , Adulto JovenRESUMEN
Excessive alternative macrophage activation contributes to fibrosis. We studied the effects of nortrachelogenin, the major lignan component of Pinus sylvestris knot extract, on alternative (M2) macrophage activation. J774 murine and THP-1 human macrophages were cultured with IL-4+IL-13 to induce alternative activation, together with the extract and its components. Effects of nortrachelogenin were also studied in bleomycin-induced murine dermal fibrosis model. Knot extract significantly decreased the expression of alternative activation markers-arginase 1 in murine macrophages (97.4 ± 1.3% inhibition at 30 µg/mL) and CCL13 and PDGF in human macrophages-as did nortrachelogenin (94.9 ± 2.4% inhibition of arginase 1 at 10 µM). Nortrachelogenin also decreased PPARγ expression but had no effect on STAT6 phosphorylation. In vivo, nortrachelogenin reduced bleomycin-induced increase in skin thickness as well as the expression of collagens COL1A1, COL1A2, and COL3A1 (all by >50%). In conclusion, nortrachelogenin suppressed IL-4+IL-13-induced alternative macrophage activation and ameliorated bleomycin-induced fibrosis, indicating therapeutic potential in fibrosing conditions.
Asunto(s)
Bleomicina/efectos adversos , Furanos/administración & dosificación , Interleucina-13/inmunología , Interleucina-4/inmunología , Lignanos/administración & dosificación , Activación de Macrófagos/efectos de los fármacos , Pinus sylvestris/química , Extractos Vegetales/administración & dosificación , Enfermedades de la Piel/tratamiento farmacológico , Animales , Colágeno/inmunología , Fibrosis/inducido químicamente , Fibrosis/tratamiento farmacológico , Fibrosis/etiología , Fibrosis/inmunología , Humanos , Interleucina-13/genética , Interleucina-4/genética , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/genética , Enfermedades de la Piel/inmunologíaRESUMEN
Glucosylceramide (GlcCer) is present in foods such as barley, corn, and wheat flour. GlcCer derived from different foods has differences in its physiological effects, depending on the sphingoid backbone and constituent fatty acids. In this study, we investigated the moisturizing and skin conditioning effects of GlcCer derived from torula yeast (Candida utilis) in healthy human subjects. The participants were randomly distributed in a crossover, double-blind comparative manner. Seventeen volunteers were orally administered both 1.8 mg/d of GlcCer derived from torula yeast and a placebo for 4 wk. Before and after oral administration, transepidermal water loss (TEWL) was measured and the objective skin condition observation and a questionnaire on skin condition were conducted. The primary endpoint was TEWL; secondary endpoints included the objective and subjective skin conditions. The change in TEWL over the study period on the forearm was -0.97±0.48 and -1.26±0.46 g/m2â¢h in the placebo and GlcCer groups, respectively, with significantly lower (p=0.01) TEWL observed in the GlcCer group. Brown spots increased in the placebo group but significantly decreased in the GlcCer group (p=0.04). Although chapped skin worsened in the placebo group, it significantly improved in the GlcCer group (p=0.04). The use of torula yeast-derived GlcCer as a functional cosmeceutical food is a viable option to ameliorate skin conditions, including improvement in skin barrier function, reduction of brown spots, and fixation of chapped skin.
Asunto(s)
Candida/química , Suplementos Dietéticos , Glucosilceramidas/uso terapéutico , Enfermedades de la Piel/terapia , Piel/fisiopatología , Adulto , Frío/efectos adversos , Estudios Cruzados , Método Doble Ciego , Femenino , Antebrazo , Humanos , Humedad/efectos adversos , Japón , Masculino , Persona de Mediana Edad , Estaciones del Año , Índice de Severidad de la Enfermedad , Piel/inmunología , Piel/metabolismo , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/metabolismo , Enfermedades de la Piel/fisiopatología , Pigmentación de la Piel , Agua/metabolismoRESUMEN
The efficacy of phototherapy is based on the interaction between ultraviolet (UV) radiation and the skin. The photobiological effects thus achieved depend on the wavelengths used. Targeted use of UVA and UVB, where indicated in combination with a photosensitizer such as psoralen, provides the dermatologist with a broad armamentarium for the treatment of a multitude of skin diseases. The spectrum of indications ranges from superficial dermatitis, psoriasis, and malignancies, such as cutaneous T-cell lymphoma, to deep sclerosing conditions such as morphea. The objective of the present review is to highlight the photobiological effects of the various types of UV radiation as well as the resultant clinical indications for phototherapy.
Asunto(s)
Enfermedades de la Piel/radioterapia , Piel/efectos de la radiación , Terapia Ultravioleta/métodos , Humanos , Fototerapia/métodos , Piel/inmunología , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/terapia , Rayos UltravioletaRESUMEN
Oral tolerance prevents allergic responses, but cutaneous exposure to food allergens predisposes individuals to food allergies. Soybean, a major allergenic food, is also an ingredient in various cosmetic products. However, it remains to be determined whether oral tolerance prevents percutaneous sensitization to soybean proteins in humans or animal models. In this study, BALB/c mice were divided into three groups; the SS group fed a soybean-containing diet, and the CS and control (C) groups fed a soybean-free diet. After being dorsally shaved, the CS and SS groups were epicutaneously exposed to a soybean extract while the control group was exposed to only the carrier. Specific IgE and IgG1 immunoglobulins secreted in response to the soybean proteins were measured using enzyme-linked immunosorbent assays. Exposure to the soybean extract elicited the secretion of IgE and IgG1 specific for Gly m 5 and Gly m 6, and trypsin inhibitor. Oral soybean consumption attenuated the secretion of all the soybean-specific IgEs and IgG1s, suggesting that percutaneous sensitization to soybean proteins is attenuated by oral tolerance.
Asunto(s)
Antígenos de Plantas/uso terapéutico , Dieta , Glycine max/química , Hipersensibilidad/prevención & control , Enfermedades de la Piel/prevención & control , Piel/efectos de los fármacos , Proteínas de Soja/uso terapéutico , Administración Cutánea , Alérgenos/administración & dosificación , Alérgenos/uso terapéutico , Animales , Antígenos de Plantas/administración & dosificación , Antígenos de Plantas/efectos adversos , Cosméticos/química , Ensayo de Inmunoadsorción Enzimática , Femenino , Hipersensibilidad a los Alimentos/inmunología , Intolerancia Alimentaria , Hipersensibilidad/metabolismo , Inmunoglobulina E/metabolismo , Inmunoglobulina G/metabolismo , Ratones Endogámicos BALB C , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/metabolismo , Proteínas de Soja/administración & dosificación , Proteínas de Soja/efectos adversos , Proteínas de Soja/inmunología , Glycine max/efectos adversos , Glycine max/inmunologíaRESUMEN
Decreased interferon (IFN)-γ levels and increased levels of macrophage-derived chemokine (MDC) and intercellular adhesion molecule (ICAM)-1 are known to be involved in allergic skin diseases, such as eczema and atopic dermatitis. Activation of the IFN-γ and its downstream interleukin-12 (IL-12) pathway can correct these diseases. Suppressor of cytokine signaling 1 (SOCS1) is a cytokine signaling inhibitor that blocks downstream pathways of IFN-γ by blocking the mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) signaling pathways. Oxymatrine (OMT), a quinolizidine alkaloid extracted from the herbal medicine Radix Sophorae flavescentis, is used to treat allergic skin diseases in China. The non-cytotoxic concentrations of OMT in HaCaT cells were determined through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Tumor necrosis factor (TNF)-α and IFN-γ were used to stimulate HaCaT cells, and OMT was added to this system with tacrolimus (FK506) as a positive control. The mRNAs of cytokines, MDC, ICAM-1, IL-12p35, IL-12p40, and IFN-γ receptor (IFN-γR)α were detected by RT-PCR. Western blot analyses were performed to assess activation of the MAPK (p38, Jun N-terminal kinase, and extracellular signal-regulated kinase) and Akt signaling pathways. OMT increased the mRNA levels of the IL-12 and IFN-γRα, reduced the mRNA levels of ICAM-1, MDC, and SOCS1. But FK506 increased the mRNA levels of IL12 and inhibited the expression of ICAM-1 mRNAs and had no effects on the IFN-γRα, MDC, and SOCS1 mRNA in HaCaT cells stimulated with TNF-α and IFN-γ. Thus, the mechanisms through which OMT and FK506 ameliorate allergic skin diseases differ.
Asunto(s)
Alcaloides/farmacología , Quinolizinas/farmacología , Enfermedades de la Piel/tratamiento farmacológico , Línea Celular , Quimiocina CCL22 , Regulación hacia Abajo/efectos de los fármacos , Humanos , Inmunosupresores , Molécula 1 de Adhesión Intercelular , Interferón gamma/metabolismo , Queratinocitos/citología , Sistema de Señalización de MAP Quinasas , ARN Mensajero/efectos de los fármacos , Enfermedades de la Piel/inmunología , Proteína 1 Supresora de la Señalización de Citocinas , Tacrolimus/farmacologíaRESUMEN
Vitamin D plays a key role in skeletal and cardiovascular disorders, cancers, central nervous system diseases, reproductive diseases, infections, and autoimmune and dermatological disorders. The two main sources of vitamin D are sun exposure and oral intake, including vitamin D supplementation and dietary intake. Multiple factors are linked to vitamin D status, such as Fitzpatrick skin type, sex, body mass index, physical activity, alcohol intake, and vitamin D receptor polymorphisms. Patients with photosensitive disorders tend to avoid sun exposure, and this practice, along with photoprotection, can put this category of patients at risk for vitamin D deficiency. Maintaining a vitamin D serum concentration within normal levels is warranted in atopic dermatitis, psoriasis, vitiligo, polymorphous light eruption, mycosis fungoides, alopecia areata, systemic lupus erythematosus, and melanoma patients. The potential determinants of vitamin D status, as well as the benefits and risks of vitamin D (with a special focus on the skin), will be discussed in this article.
Asunto(s)
Suplementos Dietéticos , Enfermedades de la Piel/tratamiento farmacológico , Deficiencia de Vitamina D/prevención & control , Vitamina D/uso terapéutico , Vitaminas/uso terapéutico , Humanos , Factores de Riesgo , Piel/inmunología , Piel/metabolismo , Piel/efectos de la radiación , Enfermedades de la Piel/sangre , Enfermedades de la Piel/complicaciones , Enfermedades de la Piel/inmunología , Pigmentación de la Piel/inmunología , Pigmentación de la Piel/efectos de la radiación , Luz Solar/efectos adversos , Vitamina D/sangre , Vitamina D/inmunología , Vitamina D/metabolismo , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/etiología , Vitaminas/sangre , Vitaminas/inmunología , Vitaminas/metabolismoRESUMEN
Psycho-Neuro-Endocrine-Immunology (P.N.E.I.) is a scientific field of study that investigates the link between bidirectional communications among the nervous system, the endocrine system, and the immune system and the correlations of this cross-talk with physical health. The P.N.E.I. innovative medical approach represents a paradigm shift from a strictly biomedical view of health and disease taken as hermetically sealed compartments to a more interdisciplinary one. The key element of P.N.E.I. approach is represented by the concept of bidirectional cross-talk between the psychoneuroendocrine and immune systems. The Low Dose Medicine is one of the most promising approaches able to allow the researchers to design innovative therapeutic strategies for the treatment of skin diseases based on the rebalance of the immune response.
Asunto(s)
Sistema Nervioso Central/fisiopatología , Sistema Endocrino/fisiopatología , Sistema Inmunológico/fisiopatología , Enfermedades de la Piel/fisiopatología , Enfermedades de la Piel/psicología , Animales , Sistema Nervioso Central/inmunología , Sistema Nervioso Central/metabolismo , Sistema Endocrino/inmunología , Sistema Endocrino/metabolismo , Salud Holística , Homeostasis , Humanos , Sistema Inmunológico/inmunología , Sistema Inmunológico/metabolismo , Neuroinmunomodulación , Sistemas Neurosecretores/inmunología , Sistemas Neurosecretores/metabolismo , Sistemas Neurosecretores/fisiopatología , Transducción de Señal , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/terapiaAsunto(s)
Transfusión de Sangre Autóloga/efectos adversos , Inmunoterapia/efectos adversos , Transfusión de Linfocitos/efectos adversos , Enfermedades de la Piel/etiología , Linfocitos T Citotóxicos/trasplante , Adulto , Anciano , Antígenos CD19 , Complejo CD3/genética , Complejo CD3/inmunología , Citocinas/metabolismo , Neoplasias Hematológicas/terapia , Humanos , Inmunoterapia/métodos , Masculino , Persona de Mediana Edad , Neoplasias Primarias Secundarias/diagnóstico , Neoplasias Primarias Secundarias/etiología , Neoplasias Primarias Secundarias/inmunología , Dominios Proteicos , Receptores de Antígenos de Linfocitos T/genética , Receptores de Antígenos de Linfocitos T/inmunología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/inmunología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/inmunología , Síndrome , Linfocitos T Citotóxicos/inmunología , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/genética , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunologíaRESUMEN
AIM: To evaluate the effect of oral Escherichia coli (E. coli) Nissle application on the outcome of intestinal-borne dermatoses. METHODS: In a randomized, controlled, non-blinded prospective clinical trial 82 patients with intestinal-borne facial dermatoses characterized by an erythematous papular-pustular rash were screened. At the initiation visit 37 patients entered the experimental arm and 20 patients constituted the control arm. All 57 patients were treated with a vegetarian diet and conventional topical therapy of the dermatoses with ointments containing tetracycline, steroids and retinoids. In the experimental arm patients received a one month therapy with oral E. coli Nissle at a maintenance dose of 2 capsules daily. The experimental group was compared to a non-treatment group only receiving the diet and topical therapy. The primary outcome parameter was improvement of the dermatoses, secondary parameters included life quality and adverse events. In addition the immunological reaction profile (IgA, interleucin-8 and interferon-α) was determined. Furthermore the changes of stool consistency and the microbiota composition over the time of intervention were recorded. RESULTS: Eighty-nine percent of the patients with acne, papular-pustular rosacea and seborrhoic dermatitis responded to E. coli Nissle therapy with significant amelioration or complete recovery in contrast to 56% in the control arm (P < 0.01). Accordingly, in the E. coli Nissle treated patients life quality improved significantly (P < 0.01), and adverse events were not recorded. The clinical improvement was associated with a significant increase of IgA levels to normal values in serum as well as suppression of the proinflammatory cytokine IL-8 (P < 0.01 for both parameters). In the E. coli Nissle treated group a shift towards a protective microbiota with predominance of bifidobacteria and lactobacteria (> 10(7) CFU/g stool) was observed in 79% and 63% of the patients, respectively (P < 0.01), compared to no change in the control group without E. coli Nissle. Moreover, the detection rate of a pathogenic flora dropped from 73% to 14 % of the patients in the experimental arm (P < 0.01) with no significant change in the control arm (accounting 80% before and 70% after the observation period, P > 0.05). Accordingly, stool consistency, color and smell normalized in the E. coli Nissle treated patients. CONCLUSION: E. coli Nissle protects the mucus barrier by overgrowth of a favorable gut microbiota with less immunoreactive potential which finally leads to clinical improvement of intestinal borne dermatoses.